Intensive Care Unit Procedure Related Infections

January 14, 2024 updated by: Mostafa Farouk, Cairo University

Procedure Related Infections in Intensive Care Unit

Objectives: To identify the rate and predictors of procedure related infection, the most causative organisms and the effect on ICU stay and in hospital mortality. To show the validity of NEW score in predicting mortality.

Methods: Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation & mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

AIM OF THE WORK

  • To identify the rate and predictors of procedure related infections in ICU after application of all preventive measures and to identify most causative organisms.
  • Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
  • To study the validity of NEW score in predicting mortality in comparison to APACHE II score .

PATIENTS AND METHODS

Study design:

This was a prospective observational study carried out at medical and cardiac intensive care units (ICUs) of 3 secondary and tertiary care hospitals from July 2022 to June 2023 and included 1040 patients.

Inclusion criteria:

All consecutive adult patients admitted to ICU who had been subjected to the following procedures:

  1. Urinary catheterization.
  2. Central venous catheter (CVC) insertion.
  3. Endotracheal intubation and mechanical ventilation.

Exclusion criteria:

  • Patients with evidence of infection prior to ICU admission.
  • Procedures done before ICU admission.

All patients were subjected to the following assessment:

A) On admission:

  • The acute physiology and chronic health evaluation II (APACHE II) score.
  • New early warning score 2 (NEWS2): NEWS ranges from 0, indicating the lowest severity of illness, to a maximum value of 20.
  • Detailed history including age, sex, medical history.
  • Complete clinical examination.
  • Chest x-ray.

B) ICU stay:

• Laboratory investigations include Complete blood count (CBC), C reactive protein (CRP), renal and liver chemistry after 2, 4, 6, 12, 18 and 24 days.

Blood, urine and sputum cultures if infection was suspected.

• Chest x-ray if chest infection suspected.

C) FOLLOW UP :

  • Length of mechanical ventilation
  • Length of ICU stay
  • Length of hospital stay
  • Morbidity & mortality

Primary outcomes:

  1. Identification of rate and predictors of procedure related infections.
  2. Identification of the most causative organisms.

Secondary outcomes:

  1. Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
  2. The validity of NEW score in predicting mortality

Definitions:

Ventilator associated pneumonia (VAP): was defined as pneumonia occurring >48 hours following endotracheal intubation when a new or progressive lung infiltrates, consolidation, or cavitation on chest X-ray develops in a patient with:

  • New onset of purulent bronchial secretions with leukopenia (white blood cells <4×109/L) or leukocytosis (>12×109/L)
  • Core temperature ≥38.5°C or ≤36°C without other cause, significant positive culture from blood, or endotracheal aspirate, broncho-alveolar lavage (BAL), or culture from another relevant site of infection [10].

Catheter associated urinary tract infection (CAUTI): A patient must meet all three criteria below:

  1. Patient had an indwelling urinary catheter that had been in place for >2 days on the date of event (day of device placement=day 1) and was either present for any portion of the calendar day on the date of event or removed the day before the date of event.
  2. Patient has at least one of the following signs or symptoms:

    fever (>38.0°C); suprapubic tenderness; costovertebral angle pain or tenderness; urinary urgency; urinary frequency; dysuria.

  3. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥105 cfu/mL.

Central line associated blood stream infection (CLABSI): A patient with a central venous catheter who has a recognized pathogen isolated from one or more blood cultures after 48 h of catheterization; or with the same skin commensals cultured from two or more blood cultures drawn on separate occasions; the pathogen is not related to an infection at another body site; and the patient has one or more of the following signs or symptoms: fever (≥38⁰c), chills, or hypotension, CLABSI was confirmed.

Statistical analysis SPSS 26.0 (SPSS Inc., an IBM Company, Chicago, IL) was used to perform the data analyses.

Baseline differences among rates were analyzed using the chi-square test for dichotomous variables and a t-test for continuous variables. 95% confidence intervals (CIs) and P values were determined for all outcomes.

Outcomes measured during the surveillance period included the incidence of overall DAIs, VAPs, CAUTIs, and CLABSIs.

DAI rates per 1,000 device-days were calculated by dividing the total number of DAIs by the total number of specific device-days and multiplying the result by 1,000 (16).

Device utilization ratios were calculated by dividing the total number of device-days by the total number of patient-days.

Device-days are the total number of days of exposure to the device (ventilator, urinary catheter, or central line) by all of the patients in the selected population during the selected time period.

Patient-days are the total number of days that patients are in an ICU during the specified time period.

Discrimination of scoring systems was assessed using the receiver operating characteristic (ROC) curve analysis for calculating the sensitivity and specificity of each score and the corresponding area under the ROC curve.

Correlations between quantitative variables were done using Spearman correlation coefficient.

Crude excess mortality of DA-HAI equals crude mortality of ICU patients with DA-HAI minus crude mortality of patients without DA-HAI.

Crude excess LOS of DA-HAI equals crude LOS of ICU patients with DA-HAI minus crude LOS of patients without DA-HAI.

Qualitative variables were presented as number and percentage (%).

Study Type

Observational

Enrollment (Actual)

1040

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11345
        • Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all ppopulations

Description

Inclusion Criteria:

  • All consecutive adult patients admitted to ICU who had been subjected to the following procedures:

    1. Urinary catheterization.
    2. Central venous catheter (CVC) insertion.
    3. Endotracheal intubation and mechanical ventilation.

Exclusion Criteria:

  • • Patients with evidence of infection prior to ICU admission.

    • Procedures done before ICU admission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of rate and predictors of procedure related infections
Time Frame: 3 months
  1. Identification of rate and predictors of procedure related infections.
  2. Identification of the most causative organisms
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1. Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
Time Frame: 3 months
2. The validity of NEW score in predicting mortality.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ahmed Mowafy, MD, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Actual)

June 30, 2023

Study Completion (Actual)

June 30, 2023

Study Registration Dates

First Submitted

December 28, 2023

First Submitted That Met QC Criteria

January 14, 2024

First Posted (Estimated)

January 17, 2024

Study Record Updates

Last Update Posted (Estimated)

January 17, 2024

Last Update Submitted That Met QC Criteria

January 14, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Kasr alainy school of medicine

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infections

Clinical Trials on monitor signs of infection

3
Subscribe